Tibsovo achieved primary endpoint in cholangiocarcinoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A global phase III ClarIDHy trial of Tibsovo (ivosidenib), sponsored by Agios Pharmaceuticals Inc., in previously treated cholangiocarcinoma patients with an isocitrate dehydrogenase 1 mutation met its primary endpoint.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Joni D. Nelson, assistant director for the Office of Workforce Development at the MUSC Hollings Cancer Center, remembers the exact day a switch went off in her head and her career took a turn towards finding ways to improve public health.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login